91 related articles for article (PubMed ID: 24659789)
21. Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Laurent J; Speiser DE; Appay V; Touvrey C; Vicari M; Papaioannou A; Canellini G; Rimoldi D; Rufer N; Romero P; Leyvraz S; Voelter V
J Immunother; 2010 Sep; 33(7):723-34. PubMed ID: 20664354
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2, killer cells and cancer therapy: an overview.
Parkinson DR; Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
[No Abstract] [Full Text] [Related]
24. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
Porter DL; June CH
Bone Marrow Transplant; 2005 May; 35(10):935-42. PubMed ID: 15806121
[TBL] [Abstract][Full Text] [Related]
25. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
26. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
27. Adoptive T-cell therapy of cancer.
Erbayraktar Z
J BUON; 2009 Sep; 14 Suppl 1():S193-201. PubMed ID: 19785066
[TBL] [Abstract][Full Text] [Related]
28. Adoptive T-cell transfer in melanoma.
Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
[TBL] [Abstract][Full Text] [Related]
29. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
30. The role of interleukin-2 in cancer immunotherapy.
Eberlein TJ; Schoof DD
Compr Ther; 1991 Jan; 17(1):49-56. PubMed ID: 2001612
[TBL] [Abstract][Full Text] [Related]
31. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
32. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
33. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
Finkelstein SE; Heimann DM; Klebanoff CA; Antony PA; Gattinoni L; Hinrichs CS; Hwang LN; Palmer DC; Spiess PJ; Surman DR; Wrzesiniski C; Yu Z; Rosenberg SA; Restifo NP
J Leukoc Biol; 2004 Aug; 76(2):333-7. PubMed ID: 15155774
[TBL] [Abstract][Full Text] [Related]
34. Trafficking of T cells into tumors.
Slaney CY; Kershaw MH; Darcy PK
Cancer Res; 2014 Dec; 74(24):7168-74. PubMed ID: 25477332
[TBL] [Abstract][Full Text] [Related]
35. Adoptive Cell Therapy for Nonhematologic Solid Tumors.
Olson DJ; Odunsi K
J Clin Oncol; 2023 Jun; 41(18):3397-3407. PubMed ID: 37104722
[TBL] [Abstract][Full Text] [Related]
36. Novel immunotherapies for the treatment of melanoma.
Gato-Cañas M; Arasanz H; Blanco-Luquin I; Glaría E; Arteta-Sanchez V; Kochan G; Escors D
Immunotherapy; 2016 May; 8(5):613-32. PubMed ID: 27140413
[TBL] [Abstract][Full Text] [Related]
37. Hit parade for adoptive cell transfer therapy: the best T cells for superior clinical responses.
Speiser DE
Cancer Discov; 2013 Apr; 3(4):379-81. PubMed ID: 23580281
[TBL] [Abstract][Full Text] [Related]
38. Toll-like receptors in tumor immunotherapy.
Paulos CM; Kaiser A; Wrzesinski C; Hinrichs CS; Cassard L; Boni A; Muranski P; Sanchez-Perez L; Palmer DC; Yu Z; Antony PA; Gattinoni L; Rosenberg SA; Restifo NP
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5280-9. PubMed ID: 17875756
[TBL] [Abstract][Full Text] [Related]
39. CD19CAR T cells: From humble beginnings to cancer immunotherapy's poster child.
Gardner RA; Jensen MC
Cancer J; 2014; 20(2):107-11. PubMed ID: 24667954
[TBL] [Abstract][Full Text] [Related]
40. Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing
Kim SH; Go EM; Shin DH; Choi BK; Han C
Cells; 2022 Dec; 11(23):. PubMed ID: 36497152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
